Tolerogenic nanovaccines for the treatment of type I allergic diseases
Journal of Controlled Release,
Год журнала:
2025,
Номер
380, С. 664 - 685
Опубликована: Фев. 17, 2025
Язык: Английский
Exosomes as Biomarkers and Therapeutic Agents in Neurodegenerative Diseases: Current Insights and Future Directions
Sam Dehghani,
Ozgecan Ocakcı,
Pars Tan Hatipoglu
и другие.
Molecular Neurobiology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 17, 2025
Abstract
Neurodegenerative
diseases
(NDs)
like
Alzheimer’s,
Parkinson’s,
and
ALS
rank
among
the
most
challenging
global
health
issues,
marked
by
substantial
obstacles
in
early
diagnosis
effective
treatment.
Current
diagnostic
techniques
frequently
demonstrate
inadequate
sensitivity
specificity,
whilst
conventional
treatment
strategies
encounter
challenges
related
to
restricted
bioavailability
insufficient
blood–brain
barrier
(BBB)
permeability.
Recently,
exosomes—nanoscale
vesicles
packed
with
proteins,
RNAs,
lipids—have
emerged
as
promising
agents
potential
reshape
therapeutic
approaches
these
diseases.
Unlike
drug
carriers,
they
naturally
traverse
BBB
can
deliver
bioactive
molecules
affected
neural
cells.
Their
molecular
cargo
influence
cell
signaling,
reduce
neuroinflammation,
potentially
slow
neurodegenerative
progression.
Moreover,
exosomes
serve
non-invasive
biomarkers,
enabling
precise
while
allowing
real-time
disease
monitoring.
Additionally,
engineered
exosomes,
loaded
molecules,
enhance
this
capability
targeting
diseased
neurons
overcoming
barriers.
By
offering
enhanced
reduced
immunogenicity,
an
ability
bypass
physiological
limitations,
exosome-based
present
a
transformative
advantage
over
existing
approaches.
This
review
examines
multifaceted
role
of
NDDs,
emphasizing
their
capabilities,
intrinsic
functions,
advanced
vehicles.
Язык: Английский
Therapeutic potential of EVs loaded with CB2 receptor agonist in spinal cord injury via the Nrf2/HO-1 pathway
Redox Report,
Год журнала:
2024,
Номер
29(1)
Опубликована: Окт. 28, 2024
Background
Spinal
cord
injury
(SCI)
poses
a
challenge
due
to
limited
treatment
options.
Recently,
the
effect
and
mechanism
of
Exo-loaded
cannabinoid
receptor
type
2
(CB2)
agonist
AM1241(Exo
+
AM1241)
have
been
applied
in
other
inflammatory
diseases
but
not
SCI.
Язык: Английский
Exosome-based therapies for inflammatory disorders: a review of recent advances
Stem Cell Research & Therapy,
Год журнала:
2024,
Номер
15(1)
Опубликована: Дек. 18, 2024
Exosomes,
small
extracellular
vesicles
secreted
by
cells,
have
emerged
as
focal
mediators
in
intercellular
communication
and
therapeutic
interventions
across
diverse
biomedical
fields.
Inflammatory
disorders,
including
inflammatory
bowel
disease,
acute
liver
injury,
lung
neuroinflammation,
myocardial
infarction,
are
complex
conditions
that
require
innovative
approaches.
This
review
summarizes
recent
advances
exosome-based
therapies
for
highlighting
their
potential
diagnostic
biomarkers
agents.
Exosomes
shown
promise
reducing
inflammation,
promoting
tissue
repair,
improving
functional
outcomes
preclinical
models
of
disorders.
However,
further
research
is
needed
to
overcome
the
challenges
associated
with
exosome
isolation,
characterization,
delivery,
well
fully
understand
mechanisms
action.
Current
limitations
future
directions
underscore
need
enhanced
isolation
techniques
deeper
mechanistic
insights
harness
exosomes'
full
clinical
applications.
Despite
these
challenges,
hold
great
treatment
disorders
may
offer
a
new
paradigm
personalized
medication.
Язык: Английский
Immunomodulatory effect of mesenchymal stem cells‐derived extracellular vesicles to modulate the regulatory T cells and Th1/Th2 imbalance in peripheral blood mononuclear cells of patients with allergic rhinitis
Scandinavian Journal of Immunology,
Год журнала:
2024,
Номер
100(6)
Опубликована: Окт. 29, 2024
Mesenchymal
stem
cell-derived
extracellular
vesicles
(MSC-EVs)
have
shown
promising
immunomodulatory
capabilities
for
a
variety
of
clinical
conditions.
However,
the
potential
regulatory
mechanisms
MSC-EVs
in
allergic
rhinitis
(AR)
remain
unexplored.
The
present
study
was
designed
to
investigate
effect
patients
with
AR.
Peripheral
blood
mononuclear
cells
(PBMCs)
were
isolated
from
AR
patients.
number
peripheral
CD4
Язык: Английский